Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E77.31 EPS (ttm)5.13 Insider Own1.10% Shs Outstand104.06M Perf Week-5.59%
Market Cap41.27B Forward P/E28.24 EPS next Y14.05 Insider Trans-15.21% Shs Float76.64M Perf Month-23.65%
Income591.20M PEG3.56 EPS next Q3.31 Inst Own72.60% Short Float4.53% Perf Quarter-29.68%
Sales3.81B P/S10.84 EPS this Y-19.40% Inst Trans-0.20% Short Ratio4.25 Perf Half Y-31.91%
Book/sh31.90 P/B12.43 EPS next Y12.11% ROA13.30% Target Price594.30 Perf Year-4.17%
Cash/sh8.61 P/C46.08 EPS next 5Y21.75% ROE19.50% 52W Range392.35 - 605.93 Perf YTD-26.94%
Dividend- P/FCF66.55 EPS past 5Y41.20% ROI12.50% 52W High-34.55% Beta1.17
Dividend %- Quick Ratio3.40 Sales past 5Y49.40% Gross Margin91.00% 52W Low1.09% ATR23.87
Employees2925 Current Ratio3.60 Sales Q/Q56.70% Oper. Margin32.30% RSI (14)28.63 Volatility5.65% 5.72%
OptionableYes Debt/Eq0.12 EPS Q/Q154.90% Profit Margin15.50% Rel Volume1.77 Prev Close412.59
ShortableYes LT Debt/Eq0.12 EarningsFeb 09 BMO Payout0.00% Avg Volume817.32K Price396.61
Recom2.20 SMA20-12.57% SMA50-21.97% SMA200-23.82% Volume1,424,000 Change-3.87%
Jan-27-16Downgrade Canaccord Genuity Buy → Hold $700 → $525
Jan-25-16Downgrade Chardan Capital Markets Neutral → Sell $525 → $400
Jan-20-16Initiated Credit Suisse Neutral
Dec-04-15Initiated Wells Fargo Outperform
Nov-05-15Reiterated RBC Capital Mkts Outperform $665 → $676
Oct-02-15Downgrade Morgan Stanley Overweight → Equal-Weight $593
Sep-01-15Initiated Raymond James Outperform $615
Aug-31-15Downgrade Chardan Capital Markets Buy → Neutral $565
Aug-10-15Reiterated ROTH Capital Neutral $495 → $527
Aug-06-15Reiterated Argus Buy $560 → $660
Aug-05-15Reiterated UBS Sell $500 → $565
Aug-05-15Reiterated RBC Capital Mkts Outperform $570 → $665
Aug-05-15Reiterated Canaccord Genuity Buy $600 → $700
Aug-05-15Reiterated Barclays Equal Weight $460 → $595
Aug-04-15Reiterated Brean Capital Buy $525 → $659
Aug-03-15Reiterated Leerink Partners Outperform $559 → $630
Jul-27-15Reiterated RBC Capital Mkts Outperform $560 → $570
Jul-22-15Initiated Northland Capital Market Perform $560
Jul-20-15Reiterated RBC Capital Mkts Outperform $550 → $560
Jul-13-15Reiterated Deutsche Bank Buy $455 → $650
Feb-06-16 08:40AM  Why Ophthotech Corporation Shares Tumbled 31% in January at Motley Fool
Feb-05-16 05:16PM  3 Things to Look for in Regeneron Pharmaceuticals Inc.'s Earnings at Motley Fool
02:20PM  Regeneron (REGN) to Report Q4 Earnings: What's in Store?
Feb-04-16 08:07AM  Valeant Pharmaceuticals: The Near-Term Growth Prospects
Feb-02-16 05:40PM  Why Regeneron Pharmaceuticals Shares Fell 23% in January at Motley Fool
04:13PM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Fi
09:30AM  Regeneron Announces Upcoming 2016 Investor Conference Presentation PR Newswire
09:04AM  Ignore Regeneron Pharmaceuticals, Inc: Here Are 3 Better Buys Right Now at Motley Fool
Jan-29-16 04:06PM  Regeneron Continues to Trade at Premium
03:25PM  Double Top Could Spell Double Trouble for Regeneron
Jan-28-16 06:00PM  Amgen, Bristol-Myers Beat Q4 Views Amid Drug-Stock Bloodbath
05:06PM  What Do Analysts Expect from Regeneron in 2016?
01:27PM  Facebook, Qualcomm, Alexion Seen Gaining From Patent Box Tax Reform
08:07AM  Eylea Could Help Regeneron Focus on the Eye Therapy Segment
Jan-27-16 05:36PM  Stocks Dive After Fed, eBay, Facebook Report, Hawaiian Flies -6.34%
03:44PM  Drug developer planning $25 million expansion in Rensselaer County at bizjournals.com
12:40PM  Regeneron Downgrade Highlights at Least Some Risks
12:31PM  Will Regenerons Earnings Continue to Impress Investors?
12:31PM  What Can Investors Expect from Regenerons 4Q15 Earnings?
10:11AM  Regeneron: A Cut With 15% Upside? at Barrons.com
10:06AM  Will Vertex Pharmaceuticals Valuation Multiple Improve?
08:51AM  Regeneron Pharms downgraded by Canaccord Genuity
Jan-26-16 01:19PM  Here Are The Most Notable Insider Transactions Hitting The Market
09:49AM  Regeneron to Report Fourth Quarter and Full Year 2015 Financial and Operating Results and Host Conference Call and Webcast on February 9, 2016 at noodls
09:30AM  Regeneron to Report Fourth Quarter and Full Year 2015 Financial and Operating Results and Host Conference Call and Webcast on February 9, 2016 PR Newswire
Jan-25-16 09:51AM  Regeneron: Sell on Patent Fears, Chardan Says at Barrons.com
Jan-21-16 02:41PM  Regeneron Pharmaceuticals Inc. Stock: Bargain or Rip-Off? at Motley Fool
11:15AM  And the No. 1 Stock Fund of 2015 Was... at The Wall Street Journal
10:10AM  Stock Market News for January 21, 2016
Jan-20-16 04:50PM  SMR Rating Uncovers Stocks With Top Sales, Margins at Investor's Business Daily
12:59PM  Medicines Company Spikes On Report Of Possible Sale at Investor's Business Daily
09:23AM  Cramer's Mad Dash: AAPL & IBM
08:21AM  Solving Pharma's Shkreli Problem at Forbes
Jan-18-16 01:00AM  FB, AMZN, DOW, DD: Jim Cramer's Views at TheStreet
Jan-15-16 06:00PM  Walgreens, CVS, Illumina, Jazz Top New Insider Trades at Investor's Business Daily
03:31PM  Biotech in bear market
08:37AM  The Best Healthcare Stocks for 2016 at Motley Fool
Jan-13-16 04:14PM  Biotech Stock Roundup: Baxalta - Shire to Combine, JPM Healthcare Conference in Focus
Jan-12-16 07:46PM  Biotech ETFs Snap Back After Undercutting Sept. Lows at Investor's Business Daily
07:01PM  Cramer: This Is Where I Say I Was Wrong at TheStreet
06:45PM  Drug Stocks Mixed On Guidance Updates at Investor's Business Daily
06:25PM  Cramer: Mea culpa! I was wrong on these 2 stocks
10:16AM  Drug pricing needs balance: Regeneron CEO
06:07AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclo
Jan-11-16 03:51AM  And the No. 1 Stock Fund of 2015 Was... at The Wall Street Journal
Jan-10-16 10:20AM  Why Opthotech Corporation Shares Skyrocketed by 75% in 2015 at Motley Fool
Jan-09-16 08:03AM  Why Regeneron Pharmaceuticals Shares Jumped 32% in 2015 at Motley Fool
Jan-08-16 10:36AM  Regeneron, Sanofi Announce FDA Has Accepted For Review BLA For Sarilumab
01:00AM  Regeneron and Sanofi Announce Sarilumab Biologics License Application Accepted for Review by US FDA PR Newswire
Jan-07-16 05:12PM  Gilead Leads 3 Drug Stocks With Top Fundamentals at Investor's Business Daily
09:30AM  Regeneron Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference PR Newswire
Jan-06-16 01:47PM  Goldman sees Facebook, Amazon, Netflix retaining star power -- but not Google at MarketWatch
10:49AM  Regeneron's Stock Just Got Slammed By A Side Effect That Wasn't at Forbes
10:49AM  Here's How Regeneron's Stock Got Slammed By A Side Effect That Wasn't at Forbes
09:03AM  Will 2016 Be Regeneron Pharmaceuticals Inc.'s Best Year Yet? at Motley Fool
Jan-05-16 11:36AM  Stick With Biotech in 2016? at Barrons.com
Jan-04-16 07:03PM  The Best Mutual Fund Giants of 2015 at Motley Fool
01:45PM  3 Stocks To Buy In A Market Crash at Motley Fool
Dec-31-15 09:43AM  Will Amgen Inc. Raise Its Dividend in 2016? at Motley Fool
Dec-30-15 04:47PM  The 5 Top-Performing Big-Cap Drug Stocks Of 2015 at Investor's Business Daily
08:06AM  5 Companies We Wish We'd Bought in 2015 at Motley Fool
Dec-28-15 09:19AM  Feuerstein's Heroes and Zeroes of Biotech Investing in 2015 at TheStreet
Dec-27-15 12:01PM  Regeneron Mourns Passing of Dr. Alfred G. Gilman, Board Member and Nobel Laureate PR Newswire
Dec-26-15 08:05AM  The Worst Regeneron Pharmaceuticals, Inc. Headlines in 2015 at Motley Fool
Dec-23-15 06:15PM  Cramer: Biotechs to load up on for 2016
12:56PM  Why Celgene May be the Best Biotech in the World
09:09AM  8 Biotech Stocks That Should Be in Your Portfolio Right Now at TheStreet
Dec-22-15 07:22AM  The Best 3 Biotech Stocks for 2016 at Motley Fool
Dec-21-15 12:17PM  What Does Gilead Want to Do? at Barrons.com
11:19AM  Why Aegerion Pharmaceuticals' Stock Bolted Higher Today at Motley Fool
09:15AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : December 21, 2015
01:05AM  Alexion Pharmaceuticals: A Top Stock of SPY
Dec-20-15 02:40PM  10 Stocks That Soared Under the Fed's QE Program at TheStreet
Dec-19-15 09:21AM  The Best Regeneron Pharmaceuticals, Inc Headlines in 2015 at Motley Fool
Dec-18-15 08:25AM  Albany outpaces New York metros in manufacturing job growth at bizjournals.com
12:48AM  A Look at FDGRXs Historical Portfolio through November 2015
Dec-17-15 05:08PM  Big Biotech Amgen Facing Pivotal Year In 2016 at Investor's Business Daily
05:03AM  A Look Inside the Sweetest Corporate Director Posts in America at Bloomberg
Dec-15-15 07:47AM  Did CVS Health Just Make a Huge Mistake? at Motley Fool
Dec-14-15 03:25PM  Latest cholesterol drug comes with a $14,600-a-year price tag at MarketWatch
08:03AM  This May Be The Fastest-Growing Biotech Stock Next Year (Hint: It's Not Gilead Sciences) at Motley Fool
12:04AM  Entresto: First-in-Class Angiotensin Receptor Neprilysin Inhibitor
Dec-12-15 02:02PM  Top FDA Drug Approvals in 2015: High Cholesterol at Motley Fool
Dec-11-15 11:49AM  Take That Amgen! UnitedHealth Chooses Regeneron's Cholesterol Drug at Barrons.com
08:15AM  [$$] UnitedHealth Selects Praluent as New Cholesterol Drug at The Wall Street Journal
01:00AM  Sanofi and Regeneron Announce UnitedHealth Group Selects Praluent® (alirocumab) Injection for Preferred Access PR Newswire
01:00AM  Regeneron and Sanofi Announce UnitedHealth Group Selects Praluent® (alirocumab) Injection for Preferred Access PR Newswire
Dec-09-15 03:04PM  European Commission Approves Amgens BLINCYTO: Stock Rises 0.2%
08:04AM  Aegerion Pharmaceuticals Lost a Third of Its Value in November: Time to Buy? at Motley Fool
Dec-08-15 01:17PM  REGENERON PHARMACEUTICALS INC Financials
08:45AM  Market Data on Movers and Shakers - Research on Mylan, Regeneron Pharmaceuticals, JetBlue Airways and Continental Resources Accesswire
Dec-07-15 11:05AM  How the Market Responded to the ECs Approval of Entresto
09:17AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : December 7, 2015
Dec-04-15 03:28PM  LinkedIn, Palo Alto, Regeneron Profit Estimates Rising at Investor's Business Daily
12:25PM  Forbes Healthcare Summit: CEOs Talk Pricing, Innovation And Their Lingering Reputation Problem at Forbes
11:16AM  Negative news, correction provide biotech buying opportunity at MarketWatch
09:55AM  What Biogens sudden cash spike could say about potential acquisitions at bizjournals.com
09:27AM  For Hepatitis C Drugs, U.S. Prices Are Cheaper Than In Europe at Forbes
08:00AM  Why Ophthotech Corporation Shares Soared Higher Last Month at Motley Fool
Dec-03-15 11:52AM  Watch List Builder: A 'Tight' Stock Screen at Investor's Business Daily
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration (AMD) and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes comprising familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. The company's trap-based clinical product candidates comprise EYLEA for the treatment of AMD and diabetic macular edema; and ZALTRAP for oncology. Its antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN727 for low-density lipoprotein cholesterol reduction and for the prevention of cardiovascular events; REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN668 for atopic dermatitis, asthma, nasal polyposis, and eosinophilic esophagitis; REGN2222 for respiratory syncytial virus; REGN1033 for skeletal muscle disorders; and REGN2176-3 and REGN910-3 antibodies for use in ophthalmology. The company is also developing REGN1908-1909, REGN1154, REGN1500, and REGN1193 antibody product candidates; REGN1400, REGN1979, and REGN2810 for oncology; and REGN475 for the treatment of pain. It has collaborations with Sanofi and Mitsubishi Tanabe Pharma Corporation; license and collaboration agreement with Bayer HealthCare; and Avalanche Biotechnologies, Inc., as well as Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McCorkle Douglas SVP Controller and Asst TreasurDec 29Option Exercise52.033,954205,72710,820Dec 29 07:44 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 29Sale552.083,9542,182,9246,866Dec 29 07:44 PM
Aberman Michael SSVP Strategy Investor RelationDec 17Option Exercise24.004,00096,00016,498Dec 18 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 16Option Exercise52.031,92199,95017,742Dec 18 04:27 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Option Exercise52.031,92199,9506,866Dec 18 04:28 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 16Option Exercise52.031,92199,950501,921Dec 18 04:26 PM
Van Plew Daniel PSVP & General Mgr Industrial ODec 16Option Exercise52.031,92199,9501,921Dec 18 04:27 PM
STAHL NEILEVP Research and DevelopmentDec 16Option Exercise52.031,92199,95027,594Dec 18 04:27 PM
BROWN MICHAEL SDirectorDec 10Option Exercise177.823,000533,4603,000Dec 11 04:14 PM
BROWN MICHAEL SDirectorDec 10Sale546.453,0001,639,3650Dec 11 04:14 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 02Sale549.0343,34823,799,539500,000Dec 04 04:13 PM
SING GEORGE LDirectorNov 18Option Exercise19.693,00059,070115,772Nov 20 04:04 PM
VAGELOS P ROYChairman of the BoardNov 18Sale587.9017,24010,135,312334,611Nov 19 04:20 PM
SING GEORGE LDirectorNov 18Sale580.00500290,0004,500Nov 20 04:04 PM
SING GEORGE LDirectorNov 18Sale580.003,0001,740,000112,772Nov 20 04:04 PM
STAHL NEILEVP Research and DevelopmentNov 09Sale560.0522,10112,377,55922,029Nov 09 05:10 PM
STAHL NEILEVP Research and DevelopmentNov 06Sale563.0020,00011,260,06844,130Nov 09 05:10 PM
STAHL NEILEVP Research and DevelopmentNov 05Option Exercise28.29100,0002,828,50097,029Nov 09 05:10 PM
VAGELOS P ROYChairman of the BoardNov 03Sale580.233,9852,312,217351,851Nov 04 04:05 PM
VAGELOS P ROYChairman of the BoardNov 02Sale580.1813,2577,691,446355,836Nov 04 04:05 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriNov 02Sale571.6143,34824,778,125543,348Nov 03 04:20 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriOct 30Option Exercise11.64182,8182,128,002682,818Nov 03 04:20 PM
BROWN MICHAEL SDirectorSep 21Option Exercise57.113,000171,3303,000Sep 22 02:39 PM
BROWN MICHAEL SDirectorSep 21Sale551.553,0001,654,6500Sep 22 02:39 PM
BAKER CHARLES ADirectorSep 17Option Exercise18.615,00093,05014,000Sep 18 04:06 PM
BAKER CHARLES ADirectorSep 17Sale550.005,0002,750,0009,000Sep 18 04:06 PM
SCHLEIFER LEONARD SPresident & CEOSep 02Option Exercise402.697,2262,909,83849,313Sep 03 04:59 PM
LAROSA JOSEPH JSVP General Counsel and SecretSep 01Option Exercise59.201,68999,98916,756Sep 02 04:04 PM
Powchik PeterSVP Clinical Development & RegAug 14Sale573.3823,48513,465,86615,821Aug 17 04:01 PM
Powchik PeterSVP Clinical Development & RegAug 13Option Exercise117.3360,3617,082,07046,299Aug 17 04:01 PM
POON CHRISTINE ADirectorAug 12Sale564.1611263,186790Aug 12 04:45 PM
POON CHRISTINE ADirectorAug 11Option Exercise273.67470128,6251,125Aug 12 04:45 PM
GILMAN ALFRED GDirectorAug 06Option Exercise57.115,000285,55013,912Aug 07 06:15 PM
Terifay Robert JSVP CommercialAug 06Sale588.9713,4237,905,78123,293Aug 07 06:14 PM
GILMAN ALFRED GDirectorAug 06Sale587.125,0002,935,6018,912Aug 07 06:15 PM
Tessier-Lavigne MarcDirectorAug 05Option Exercise57.115,000285,5506,187Aug 05 08:55 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 05Option Exercise270.435,0001,352,1509,745Aug 05 08:58 PM
Landry Robert ESVP Finance & CFOAug 05Option Exercise272.704,0001,090,80011,099Aug 06 09:00 PM
Terifay Robert JSVP CommercialAug 05Option Exercise30.6332,500995,47552,529Aug 07 06:14 PM
Landry Robert ESVP Finance & CFOAug 05Sale592.844,0002,371,3507,099Aug 06 09:00 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 05Sale585.535,0002,927,6484,945Aug 05 08:58 PM
Tessier-Lavigne MarcDirectorAug 05Sale590.265,0002,951,2751,187Aug 05 08:55 PM
GOLDSTEIN JOSEPH LDirectorAug 04Sale586.002,0001,172,00014,000Aug 05 10:03 AM
GOLDSTEIN JOSEPH LDirectorJul 15Sale550.002,0001,100,00016,000Jul 15 04:09 PM
GOLDSTEIN JOSEPH LDirectorJun 22Sale526.852,0001,053,70018,000Jun 22 05:02 PM
SING GEORGE LDirectorMay 27Option Exercise19.695,00098,450117,772May 29 04:19 PM
INGRAM ROBERT ALEXANDERDirectorMay 27Sale513.391,379707,9651,500May 27 04:02 PM
SING GEORGE LDirectorMay 27Sale515.005,0002,575,000112,772May 29 04:19 PM
McCorkle Douglas SVP Controller and Asst TreasurMay 22Option Exercise174.0113,4642,342,90217,481May 26 04:31 PM
INGRAM ROBERT ALEXANDERDirectorMay 22Option Exercise293.536,6671,956,9656,667May 27 04:02 PM
McCorkle Douglas SVP Controller and Asst TreasurMay 22Sale515.6013,0006,702,8004,481May 26 04:31 PM
GOLDSTEIN JOSEPH LDirectorMay 22Sale514.284,0002,057,10020,000May 26 04:30 PM
BROWN MICHAEL SDirectorMay 15Option Exercise57.115,000285,5505,000May 18 04:50 PM
BROWN MICHAEL SDirectorMay 15Sale495.005,0002,475,0000May 18 04:50 PM
Landry Robert ESVP Finance & CFOApr 08Option Exercise272.7010,0002,727,00015,000Apr 09 04:03 PM
BAKER CHARLES ADirectorMar 25Option Exercise18.615,00093,05014,000Mar 26 04:20 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 25Option Exercise59.203,097183,34215,067Mar 26 04:21 PM
BAKER CHARLES ADirectorMar 25Sale454.965,0002,274,7859,000Mar 26 04:20 PM
Aberman Michael SSVP Strategy Investor RelationMar 24Sale478.994,8432,319,73812,498Mar 25 04:07 PM
Aberman Michael SSVP Strategy Investor RelationMar 18Sale465.003,4421,600,54222,498Mar 19 04:05 PM
Aberman Michael SSVP Strategy Investor RelationMar 17Option Exercise24.0011,398273,55229,998Mar 19 04:05 PM
Terifay Robert JSVP CommercialMar 17Sale451.0110,9934,957,90720,029Mar 18 06:03 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 16Option Exercise59.2020,2811,200,63528,311Mar 17 04:57 PM
Terifay Robert JSVP CommercialMar 16Option Exercise30.6324,375746,60644,404Mar 18 06:03 PM
LAROSA JOSEPH JSVP General Counsel and SecretMar 16Sale450.0018,3118,239,95010,000Mar 17 04:57 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 27Sale416.243,0001,248,7204,481Feb 27 04:31 PM
Tessier-Lavigne MarcDirectorFeb 26Option Exercise50.913,000152,7304,187Feb 27 04:32 PM
Tessier-Lavigne MarcDirectorFeb 26Sale421.953,0001,265,8641,187Feb 27 04:32 PM
Aberman Michael SSVP Strategy Investor RelationFeb 24Sale418.483,3741,411,95218,600Feb 25 04:02 PM
Terifay Robert JSVP CommercialFeb 24Sale423.6711,1734,733,66520,029Feb 25 04:01 PM
Aberman Michael SSVP Strategy Investor RelationFeb 23Option Exercise30.637,500229,72526,100Feb 25 04:02 PM
Terifay Robert JSVP CommercialFeb 23Option Exercise30.6324,375746,60644,404Feb 25 04:01 PM
Van Plew Daniel PSVP & General Mgr Industrial OFeb 23Sale427.829,4314,034,75418,705Feb 24 05:08 PM
RYAN ARTHUR FDirectorFeb 20Option Exercise125.7929,2503,679,49876,750Feb 23 04:06 PM
BROWN MICHAEL SDirectorFeb 20Option Exercise57.111,00057,1101,000Feb 23 04:07 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Option Exercise177.825,000889,1009,000Feb 20 04:44 PM
Van Plew Daniel PSVP & General Mgr Industrial OFeb 20Option Exercise21.2520,000425,00038,705Feb 24 05:08 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Sale423.655,0002,118,2624,000Feb 20 04:44 PM
BROWN MICHAEL SDirectorFeb 20Sale422.721,000422,7200Feb 23 04:07 PM
RYAN ARTHUR FDirectorFeb 20Sale423.0129,25012,372,90847,500Feb 23 04:06 PM
Aberman Michael SSVP Strategy Investor RelationFeb 17Sale404.463,6921,493,26618,600Feb 18 04:40 PM
Aberman Michael SSVP Strategy Investor RelationFeb 13Option Exercise24.007,500180,00026,100Feb 18 04:40 PM